SUPPLEMENTAL MATERIAL

Inhibition of NMDA receptor function with an anti-GluN1-S2 antibody impairs human platelet function and thrombosis

Taryn N. Green¹, Justin R. Hamilton², Marie-Christine Morel-Kopp^{3,4}, Zhaohua Zheng², Ting-Yu T. Chen^{1,5}, James I. Hearn¹, Peng P. Sun¹, Jack U. Flanagan^{6,7}, Deborah Young⁵,

P. Alan Barber^{5,8}, Matthew J. During^{1,9}, Christopher M. Ward^{3.4} & Maggie L. Kalev-Zylinska^{1,10}

¹Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand;

²Australian Centre for Blood Diseases, Monash University, Melbourne, Australia;

³Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, Sydney, Australia;

⁴Northern Blood Research Centre, Kolling Institute, University of Sydney, Sydney, Australia;

⁵Centre for Brain Research, University of Auckland, Auckland, New Zealand;

⁶Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand;

⁷Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand;

⁸Department of Neurology, Auckland City Hospital, Auckland, New Zealand;

⁹Departments of Molecular Virology, Immunology and Medical Genetics, Neuroscience and Neurological Surgery, Ohio State University, Columbus, OH, USA;

¹⁰LabPlus Haematology, Auckland City Hospital, Auckland, New Zealand.

Correspondence: Maggie L. Kalev-Zylinska, Department of Molecular Medicine and Pathology, University of Auckland, ACM 1142, Auckland, New Zealand. Tel.: +6421337776; Fax: +6493677121; E-mail: <u>m.kalev@auckland.ac.nz.</u>

Supplemental Methods

Mapping of anti-GluN1 epitopes

The epitopes of anti-GluN1 antibodies were mapped by an antigen-capture ELISA using a library of 74 overlapping synthetic peptides spanning all extracellular regions of the GluN1 protein (Mimotopes, PepSetsTM, Melbourne, Australia; Supplemental Table S1). The 13 aa linker was included in the library although it was not a part of the native protein. Each synthetic peptide was 16 aa long, containing hexamer repeats overlapping the adjacent peptides at both ends and a biotin label at the 5'-end.

Microtitre plates (Nunc Maxisorp; ThermoFisher Scientific, Rockford, IL) were coated with streptavidin (5 μ g per well) at 37°C for 4 h. Plates were washed and stored at 4°C until use (up to a month). Prior to epitope profiling, plates were blocked with 5% (weight per volume [w/v]) skim milk in 1x PBS containing 0.05% Tween20 (PBS-T). Blocking was conducted overnight at 4°C with gentle shaking. Plates were washed 3 times for 5 min in 1x PBS-T and coated with biotinylated peptides (250 pmol per well) in 1x PBS at room temperature for 3 h; triplicate wells were coated with each peptide. The antibody diluent was applied to control wells to obtain background absorbance. Plates were washed as above.

Pooled rat sera were diluted 1:200 in 1% skim milk (w/v) in 1x PBS-T. The anti-GluN1-S2 (BD556038; BD Biosciences, San Jose, CA) was diluted 1:500 and control samples (pools of human sera previously identified as positive and negative) 1:100. Samples were applied to wells in triplicates and incubated overnight at 4°C with gentle shaking. Plates were washed and secondary peroxidase-conjugated antibodies applied diluted 1:10,000 in 1x PBS-T (anti-rat, Sigma-Aldrich, Saint Louis, MO; anti-mouse, Jackson ImmunoResearch, West Grove, PA; and anti-human, Sigma-Aldrich). Plates were incubated at room temperature for 3 h and washed as above. O-phenylenediamine dihydrochloride (OPD) was added as a substrate and plates were incubated at 450 nm using Gen5 v1.04.5 software (BioTek Instruments Inc., Winooski, VT). Antibody levels were expressed as Z-scores calculated relative to the negative control, with a positivity threshold set greater than 2x SD from the mean of negative controls.

Supplemental Tables

No.	Hydro	MW	Peptide sequence	No.	Hydro	MW	Peptide sequence	
1	0.64	2,402.9	STMHLLTFALLFSCSF	38	0.33	2,337.7	VIPNDRKIIWPGGETE	
2	0.52	2,241.7	LFSCSFARAACDPKIV	39	0.04	2,307.6	PGGETEKPRGYQMSTR	
3	0.34	2,227.7	CDPKIVNIGAVLSTRK	40	0.38	2,457.9	YQMSTRLKIVTIHQEP	
4	0.18	2,458.8	VLSTRKHEQMFREAVN	41	0.41	2,405.8	TIHQEPFVYVKPTMSD	
5	0.06	2,441.7	FREAVNQANKRHGSWK	42	0.18	2,300.6	KPTMSDGTCKEEFTVN	
6	0.29	2,348.6	RHGSWKIQLNATSVTH	43	0.31	2,292.6	EEFTVNGDPVKKVICT	
7	0.35	2,182.5	ATSVTHKPNAIQMALS	44	0.23	2,114.4	KKVICTGPNDTSPGSP	
8	0.54	2,249.6	IQMALSVCEDLISSQV	45	0.37	2,203.5	TSPGSPRHTVPQCCYG	
9	0.61	2,238.6	LISSQVYAILVSHPPT	46	0.72	2,299.8	PQCCYGFCVDLLIKLA	
10	0.40	2,256.5	VSHPPTPNDHFTPTPV	47	0.51	2,462.9	LLIKLARTMNFTYEVH	
11	0.55	2,330.7	FTPTPVSYTAGFYRIP	48	0.38	2,325.6	FTYEVHLVADGKFGTQ	
12	0.58	2,337.8	GFYRIPVLGLTTRMSI	49	-0.12	2,349.6	GKFGTQERVNNSNKKE	
13	0.38	2,399.8	TTRMSIYSDKSIHLSF	50	0.20	2,351.7	NSNKKEWNGMMGELLS	
14	0.50	2,395.7	SIHLSFLRTVPPYSHQ	51	0.53	2,158.6	MGELLSGQADMIVAPL	
15	0.49	2,494.9	PPYSHQSSVWFEMMRV	52	0.47	2,359.8	MIVAPLTINNERAQYI	
16	0.70	2,592.1	FEMMRVYNWNHIILLV	53	0.22	2,504.8	ERAQYIEFSKPFKYQG	
17	0.32	2,287.6	HIILLVSDDHEGRAAQ	54	0.46	2,387.9	PFKYQGLTILVKKEIP	
18	0.02	2,412.7	EGRAAQKRLETLLEER	55	0.28	2,389.8	VKKEIPRSTLDSFMQP	
19	0.19	2,433.8	TLLEERESKAEKVLQF	56	0.29	2,317.5	DSFMQPFQSTLSTEGE	
20	0.29	2,273.6	EKVLQFDPGTKNVTAL	57	0.28	2,284.5	LSTEGEVNAEEEGFFL	
21	0.20	2,343.7	KNVTALLMEARDLEAR	58	0.32	2,463.8	EEGFFLVLDRPEERIT	
22	0.20	2,315.6	RDLEARVIILSASEDD	59	0.13	2,390.7	PEERITGINDPRLRNP	
23	0.16	2,142.3	SASEDDAATVYRAAAM	60	0.25	2,418.8	PRLRNPSDKFIYATVK	
24	0.47	2,304.7	YRAAAMLNMTGSGYVW	61	0.34	2,459.8	IYATVKQSSVDIYFRR	
25	0.34	2,236.5	GSGYVWLVGEREISGN	62	0.30	2,628.0	DIYFRRQVELSTMYRH	
26	0.30	2,258.6	REISGNALRYAPDGII	63	0.13	2,468.8	STMYRHMEKHNYESAA	
27	0.33	2,165.5	APDGIIGLQLINGKNE	64	0.05	2,292.5	NYESAAEAIQAVRDNK	
28	0.20	2,124.3	INGKNESAHISDAVGV	65	0.37	2,355.7	AVRDNKLHAFIWDSAV	
29	0.38	2,150.4	SDAVGVVAQAVHELLE	66	0.37	2,354.6	IWDSAVLEFEASQKCD	
30	0.19	2,360.6	VHELLEKENITDPPRG	67	0.37	2,328.7	ASQKCDLVTTGELFFR	
31	0.29	2,272.6	TDPPRGCVGNTNIWKT	68	0.32	2,330.7	GELFFRSGFGIGMRKD	
32	0.48	2,404.9	TNIWKTGPLFKRVLMS	69	0.25	2,359.7	IGMRKDSPWKQNVSLS	
33	0.15	2,281.7	KRVLMSSKYADGVTGR	70	0.35	2,317.6	QNVSLSILKSHENGFM	
34	-0.06	2,307.5	DGVTGRVEFNEDGDRK	71	0.25	2,553.8	HENGFMEDLDKTWVRY	
35	0.16	2,414.7	EDGDRKFANYSIMNLQ	72	0.15	2,453.7	KTWVRYQECDSRSNAP	
36	0.42	2,389.8	SIMNLQNRKLVQVGIY	73	0.22	2,355.6	SRSNAPATLTFE	
37	0.34	2,295.6	VQVGIYNGTHVIPNDR	74	0.33	2,328.5	APATLTFE	

Table S1. Sequences of synthetic peptides generated to span extracellular regions of GluN1.

	Experimental groups			Statistical analysis			
	Vehicle	Luciferase	GluN1	P value (1-way ANOVA)	P value post-hoc (Veh : GluN1)*	P value post-hoc (Luc : GluN1)*	
Haemoglobin (g L ⁻¹)	154 ± 2	152 ± 1	148 ± 2	0.0735	0.0718	0.2324	
Mean Cell Volume (fL)	53.5 ± 0.5	51.1 ± 0.6	50.5 ± 0.5	0.0013	0.0016	0.7511	
Mean Cell Haemoglobin (pg)	18.1 ± 0.2	17.5 ± 0.2	17.3 ± 0.2	0.0093	0.0086	0.6764	
Platelet count $(x10^9 L^{-1})$	933 ± 25	835 ± 75	932 ± 51	0.3722	0.9998	0.4391	
Mean Platelet Volume (fL)	8.0 ± 0.1	8.3 ± 0.1	8.2 ± 0.2	0.2370	0.3819	0.9393	
White Cell Count $(x10^9 L^{-1})$	10.36 ± 0.76	12.55 ± 1.16	15.73 ± 1.60	0.0194	0.0155	0.1803	
Neutrophil count $(x10^9 L^{-1})$	1.56 ± 0.14	2.92 ± 0.20	5.83 ± 0.74	<0.0001	<0.0001	0.0003	
Lymphocyte count $(x10^9 L^{-1})$	8.13 ± 0.70	8.56 ± 0.97	8.87 ± 0.88	0.8340	0.8195	0.9634	
Reticulocyte count (%)	2.91 ± 0.05	3.09 ± 0.08	3.05 ± 0.09	0.3114	0.4872	0.9347	
Reticulocyte-Haemoglobin (Ret-He; pg)	20.9 ± 0.3	20.6 ± 0.2	20.2 ± 0.2	0.1314	0.1178	0.3904	
Ferritin (ng mL ⁻¹)	997.0 ± 192.5	1009.9 ± 78.9	1006.4 ± 236.3	0.9988	0.9994	>0.9999	

Table S2. Haematological parameters in rats vaccinated with recombinant GluN1 peptides and controls in week 10.

*One-way ANOVA with Dunnett's post-hoc.

Abbreviations: Luc, luciferase; Veh, vehicle.

	Experimental groups			Statistical analysis			
	Vehicle	Luciferase	GluN1	P value (1-way ANOVA)	P value post-hoc (Veh : GluN1)*	P value post-hoc (Luc : GluN1)*	
Haemoglobin (g L ⁻¹)	153 ± 1	149 ± 2	148 ± 2	0.1293	0.1161	0.8026	
Mean Cell Volume (fL)	53.4 ± 0.7	50.7 ± 0.6	48.7 ± 0.7	0.0001	<0.0001	0.0894	
Mean Cell Haemoglobin (pg)	17.9 ± 0.2	17.2 ± 0.2	16.6 ± 0.2	0.0004	0.0003	0.0927	
Platelet count $(x10^9 L^{-1})$	930 ± 67	883 ± 54	899 ± 47	0.8431	0.9174	0.9777	
Mean Platelet Volume (fL)	8.3 ± 0.1	8.4 ± 0.1	8.1 ± 0.1	0.4204	0.7187	0.3934	
White Cell Count (x10 ⁹ L ⁻¹)	12.49 ± 0.80	14.07 ± 1.07	13.98 ± 1.29	0.5981	0.6563	0.9977	
Neutrophil count $(x10^9 L^{-1})$	2.07 ± 0.17	2.71 ± 0.18	4.22 ± 0.49	0.0007	0.0009	0.0089	
Lymphocyte count $(x10^9 L^{-1})$	9.27 ± 0.78	9.76 ± 0.88	8.48 ± 0.90	0.5580	0.8163	0.5320	
Reticulocyte count (%)	2.58 ± 0.08	2.58 ± 0.16	2.57 ± 0.07	0.9982	0.9981	0.9992	
Reticulocyte-Haemoglobin (Ret-He; pg)	20.4 ± 0.2	20.3 ± 0.2	19.7 ± 0.2	0.0302	0.0356	0.0931	
Ferritin (ng mL ⁻¹) †	1029.1 ± 199.8	685.0 ± 71.9	338.4 ± 43.8	0.0004	0.0004	0.0092	

Table S3. Haematological parameters in rats vaccinated with recombinant GluN1 peptides and controls in week 20.

*One-way ANOVA with Dunnett's *post-hoc*. †Data was transformed.

Abbreviations: Luc, luciferase; Veh, vehicle.

Supplemental Figures and Figure Legends:



Figure S1. Gating on platelets by flow cytometry. Dot plots are shown demonstrating platelet gates based on: (A) forward and side scatter characteristics (FSC-A – SSC-A); (B) CD61 expression (CD61-PerCP) and FSC-A. Doublets were excluded based on SSC-H – SSC-A and FSC-H – FSC-A characteristics (not shown). (C) An example of CD62P expression and PAC-1 binding on platelets activated with 2.5 M μ M ADP (green) and non-activated controls (grey).



Figure S2. Inhibition of aggregation by anti-GluN1-S2 in the presence of collagen and PAR1-AP. Human platelets were pre-treated with either anti-GluN1-S2 (0.4 and 4 μ g mL⁻¹) or control mouse IgG (4 μ g mL⁻¹) and platelet aggregation was induced using collagen (0.5-1 μ g mL⁻¹) or PAR1-AP (7-15 μ M). Representative examples of aggregation traces are shown. In the presence of PAR1-AP, responses varied between donors from minimal, mild to marked. Arrowheads point to signs of platelet disaggregation occurring over time.



Figure S3. Titration of effects by anti-GluN1-S2 on platelet aggregation. Aggregation was induced using (A) adrenaline (5-10 μ M), (B) ADP (2.5-10 μ M), (C) collagen (0.5-1 μ g mL⁻¹) and (D) PAR1-AP (7-15 μ M) in the presence of anti-GluN1-S2 from 0.004 to 0.4 μ g mL⁻¹. Representative examples of aggregation traces are shown. Inhibition of aggregation by anti-GluN1-S2 was concentration-dependent and most potent in the presence of adrenaline and ADP.

Α





Figure S4. Identification of the anti-GluN1-S2 (BD) epitope. (A) An image of an antigencapture ELISA plate showing strong and specific binding of anti-GluN1-S2 (BD Biosciences; diluted at 1:500) to peptide number 64 (P64). Numbers P58 to P68 refer to synthetic GluN1 peptides used to map the antibody epitope (sequences are in Table S1). Wells were coated with each peptide in triplicates. Yellow colour indicates reactive wells. Pooled reactive and non-reactive sera were used as positive and negative controls, respectively (PC and NC; diluted 1:100). (B) Levels of antibody binding with selected synthetic GluN1 peptides (as indicated) quantified relative to the negative control (Z-score).

Supplemental Video S1. Thrombus formation in flowing human blood under control conditions. Human whole blood was pre-treated with normal mouse IgG (10 μ g mL⁻¹) and perfused over microcapillary slides coated with type I collagen at a shear rate of 1800 s⁻¹.

Supplemental Video S2. Impact of anti-GluN1-S2 on thrombus formation in flowing human blood. Human whole blood was pre-treated with anti-GluN1-S2 (10 μ g mL⁻¹) and perfused over microcapillary slides coated with type I collagen at a shear rate of 1800 s⁻¹. Compared with control thrombi seen in Supplemental Video S1, thrombi forming in the presence of anti-GluN1-S2 are less dense and unstable; platelets are seen to detach from the initially formed thrombi.